Otsuka American Pharmaceutical is tracking payer practices and attitudes about digital therapeutics with a series of four surveys.
A survey of 110 payer decision-makers shows grow digital therapeutics for heart-related conditions and diabetes, a shift away from ad-hoc methods of evaluation of the therapeutics and an openness to conducting pilot programs with manufacturers.
https://www.managedhealthcareexecutive.com/view/payers-warm-to-prescription-digital-therapeutics-but-prize-real-world-evidence-pilot-projects-survey-shows